These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 34372782)

  • 41. Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice.
    Coleman CI; Peacock WF; Antz M
    Heart Lung Circ; 2018 Mar; 27(3):390-393. PubMed ID: 28528780
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of a Pharmacist-Led Educational Interventional Program on Electronic Monitoring-assessed Adherence to Direct Oral Anticoagulants: A Randomized, Controlled Trial in Patients with Nonvalvular Atrial Fibrillation.
    Shiga T; Kimura T; Fukushima N; Yoshiyama Y; Iwade K; Mori F; Ajiro Y; Haruta S; Yamada Y; Sawada E; Hagiwara N;
    Clin Ther; 2022 Nov; 44(11):1494-1505. PubMed ID: 36244853
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.
    Alamneh EA; Chalmers L; Bereznicki LR
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28177198
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expanding Indications of Nonvitamin K Oral Anticoagulants Beyond Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Review of Emerging Clinical Evidence.
    Hajra A; Ujjawal A; Ghalib N; Chowdhury S; Biswas S; Balasubramanian P; Gupta R; Aronow WS
    Curr Probl Cardiol; 2024 Jan; 49(1 Pt A):102017. PubMed ID: 37544618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
    Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
    Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antithrombotic treatment patterns in patients with atrial fibrillation in Italy pre- and post-DOACs: the REPAIR study.
    Esposti LD; Briere JB; Bowrin K; Diego S; Perrone V; Pasquale GD
    Future Cardiol; 2019 Mar; 15(2):109-118. PubMed ID: 30663889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Bartels DB; Lip GY;
    J Am Coll Cardiol; 2017 Feb; 69(7):777-785. PubMed ID: 28209218
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Coronary artery disease in outpatients with nonvalvular atrial fibrillation: results from the multicenter RAMSES study.
    Dogan V; Başaran Ö; Beton O; Tekinalp M; Bolat I; Kalaycioğlu E; Aykan AÇ; Taşar O; Şafak Ö; Kalçik M; Yaman M; Kirma C; Biteker M
    Coron Artery Dis; 2016 Sep; 27(6):497-503. PubMed ID: 27182772
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma C; Zint K; Elsaesser A; Bartels DB; Lip GY;
    Am J Med; 2015 Dec; 128(12):1306-13.e1. PubMed ID: 26239094
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation - a network meta-analysis of real-world data.
    Hirschl M; Kundi M
    Vasa; 2019 Mar; 48(2):134-147. PubMed ID: 30376416
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study).
    Başaran Ö; Beton O; Doğan V; Tekinalp M; Aykan AÇ; Kalaycıoğlu E; Bolat İ; Taşar O; Şafak Ö; Kalçık M; Yaman M; Altun İ; Soylu MÖ; Kırma C; Biteker M;
    Anatol J Cardiol; 2016 Oct; 16(10):734-741. PubMed ID: 27723665
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
    CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Health-related quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status.
    Varona JF; Seguí-Ripoll JM; Lozano-Duran C; Cuadrado-Gómez LM; Montagud-Moncho JB; Ramos-Guerrero A; Mirete-Ferrer JC; Donado E; García-Alegría J;
    Health Qual Life Outcomes; 2020 Dec; 18(1):383. PubMed ID: 33308246
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.
    Apenteng PN; Gao H; Hobbs FR; Fitzmaurice DA;
    BMJ Open; 2018 Jan; 8(1):e018905. PubMed ID: 29331969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 57. Trends of Antithrombotic Treatment in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
    Benetou DR; Varlamos C; Ktenas D; Tsiafoutis I; Koutouzis M; Bampali T; Mantis C; Zarifis J; Skalidis E; Aravantinos D; Varvarousis D; Lianos I; Kanakakis J; Pisimisis E; Ziakas A; Davlouros P; Alexopoulos D;
    Cardiovasc Drugs Ther; 2021 Feb; 35(1):11-20. PubMed ID: 33034806
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study.
    Xiang W; Zhang J; Liu M; Liu F; Feng X; Wang Y
    Clin Interv Aging; 2015; 10():515-9. PubMed ID: 25767378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea.
    Bae HJ; Heo JH; Jung KH; Lee YS; Hong KS; Seo WK; Koo J; Cha JK; Lee MJ; Seo BJ; Kim YJ; Kang S; Seok J; Lee J; Chung CS
    PLoS One; 2018; 13(11):e0202803. PubMed ID: 30388109
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.